Literature DB >> 34295564

Profiles of immune infiltration in the tumor microenvironment of hepatocellular carcinoma.

Lei Meng1,2, Rulan Ma2, Rong Yan2, Dawei Yuan2, Yijun Li3, Lei Shi4, Kang Li2.   

Abstract

BACKGROUND: Thus far, few studies have systematically analyzed the profiles of immune cells infiltrated in the tumor microenvironment (TME) of hepatocellular carcinoma (HCC). Therefore, the purpose of our study was to comprehensively analyze the 22 tumor-infiltrating immune cells (TIICs) and the immune subtypes of HCC, as well as the factors associated with the prognosis of HCC patients.
METHODS: In this study, we evaluated the abundance of 22 tumor-infiltrating immunocytes of 371 HCC patients from The Cancer Genome Atlas (TCGA) database by using the CIBERSORT algorithm, and defined immune subtypes of HCC according to unsupervised cluster analysis. The immune score of HCC patients was calculated by the prognostic regression model, while the survival analysis was evaluated by the Kaplan-Meier method. In addition, the consistency index of TIICs and principal component analysis (PCA) of immunomodulator genes were estimated.
RESULTS: The results of this study showed that three distinct immune subtypes of HCC were stratified, and the C1 subtype and C3 subtype were correlated with a good prognosis. The cellular composition of three immune subtypes was different. Moreover, immunomodulator gene and programmed cell death protein 1/programmed death-ligand 1 (PD-1/PD-L1) expression in the C1 subtype was significantly higher (P<0.05).
CONCLUSIONS: This suggested that the low immune score of HCC patients is associated with better clinical outcomes. In addition, the interaction network of cluster of differentiation CD8+ T cells was mainly concentrated in the C1 subtype. Taken together, this study showed that tumor-infiltrating immune cells can perhaps be an important determinant of clinical outcomes of patients with HCC and may provide biomarkers to reflect the immunotherapy response. Notably, the C1 subtype of HCC may be used as an important predictive factor for immunotherapy response. 2021 Journal of Gastrointestinal Oncology. All rights reserved.

Entities:  

Keywords:  Immunomodulator; immune checkpoint inhibitors (ICIs); immune score; liver tumor; unsupervised cluster analysis

Year:  2021        PMID: 34295564      PMCID: PMC8261307          DOI: 10.21037/jgo-21-291

Source DB:  PubMed          Journal:  J Gastrointest Oncol        ISSN: 2078-6891


  37 in total

1.  Editorial overview: Immunomodulation: Striking the right balance: using immunomodulators to target infectious diseases, cancer, and autoimmunity.

Authors:  Ed C Lavelle; James B McLachlan
Journal:  Curr Opin Pharmacol       Date:  2018-08       Impact factor: 5.547

Review 2.  PD-1/PD-L1 Pathway in Breast Cancer.

Authors:  Florian Schütz; Stefan Stefanovic; Luisa Mayer; Alexandra von Au; Christoph Domschke; Christof Sohn
Journal:  Oncol Res Treat       Date:  2017-03-27       Impact factor: 2.825

Review 3.  PD-1/PD-L1 and immunotherapy for pancreatic cancer.

Authors:  Mengyu Feng; Guangbing Xiong; Zhe Cao; Gang Yang; Suli Zheng; Xujun Song; Lei You; Lianfang Zheng; Taiping Zhang; Yupei Zhao
Journal:  Cancer Lett       Date:  2017-08-18       Impact factor: 8.679

4.  Intratumoral CD3 and CD8 T-cell Densities Associated with Relapse-Free Survival in HCC.

Authors:  Andrew Gabrielson; Yunan Wu; Hongkun Wang; Jiji Jiang; Bhaskar Kallakury; Zoran Gatalica; Sandeep Reddy; David Kleiner; Thomas Fishbein; Lynt Johnson; Eddie Island; Rohit Satoskar; Filip Banovac; Reena Jha; Jaydeep Kachhela; Perry Feng; Tiger Zhang; Anteneh Tesfaye; Petra Prins; Christopher Loffredo; John Marshall; Louis Weiner; Michael Atkins; Aiwu Ruth He
Journal:  Cancer Immunol Res       Date:  2016-03-11       Impact factor: 11.151

Review 5.  The tumor microenvironment in hepatocellular carcinoma: current status and therapeutic targets.

Authors:  Ju Dong Yang; Ikuo Nakamura; Lewis R Roberts
Journal:  Semin Cancer Biol       Date:  2010-10-12       Impact factor: 15.707

6.  Effects of infiltrating lymphocytes and estrogen receptor on gene expression and prognosis in breast cancer.

Authors:  Alberto Calabrò; Tim Beissbarth; Ruprecht Kuner; Michael Stojanov; Axel Benner; Martin Asslaber; Ferdinand Ploner; Kurt Zatloukal; Hellmut Samonigg; Annemarie Poustka; Holger Sültmann
Journal:  Breast Cancer Res Treat       Date:  2008-07-01       Impact factor: 4.872

7.  Immunodominance and functional alterations of tumor-associated antigen-specific CD8+ T-cell responses in hepatocellular carcinoma.

Authors:  Tobias Flecken; Nathalie Schmidt; Sandra Hild; Emma Gostick; Oliver Drognitz; Robert Zeiser; Peter Schemmer; Helge Bruns; Thomas Eiermann; David A Price; Hubert E Blum; Christoph Neumann-Haefelin; Robert Thimme
Journal:  Hepatology       Date:  2014-02-20       Impact factor: 17.425

8.  A classification based on tumor budding and immune score for patients with hepatocellular carcinoma.

Authors:  Li Wei; Zhang Delin; Yuan Kefei; Wu Hong; Huang Jiwei; Zhang Yange
Journal:  Oncoimmunology       Date:  2019-11-07       Impact factor: 8.110

9.  Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1.

Authors:  David A Barbie; Pablo Tamayo; Jesse S Boehm; So Young Kim; Susan E Moody; Ian F Dunn; Anna C Schinzel; Peter Sandy; Etienne Meylan; Claudia Scholl; Stefan Fröhling; Edmond M Chan; Martin L Sos; Kathrin Michel; Craig Mermel; Serena J Silver; Barbara A Weir; Jan H Reiling; Qing Sheng; Piyush B Gupta; Raymond C Wadlow; Hanh Le; Sebastian Hoersch; Ben S Wittner; Sridhar Ramaswamy; David M Livingston; David M Sabatini; Matthew Meyerson; Roman K Thomas; Eric S Lander; Jill P Mesirov; David E Root; D Gary Gilliland; Tyler Jacks; William C Hahn
Journal:  Nature       Date:  2009-10-21       Impact factor: 49.962

10.  Gene co-expression modules as clinically relevant hallmarks of breast cancer diversity.

Authors:  Denise M Wolf; Marc E Lenburg; Christina Yau; Aaron Boudreau; Laura J van 't Veer
Journal:  PLoS One       Date:  2014-02-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.